Microscopic yeast have been wreaking havoc in hospitals around the world—creeping into catheters, ventilator tubes, and IV lines—and causing deadly invasive infection. One culprit species, Candida auris, is resistant to many antifungals, meaning once a person is infected, there are limited treatment options. But in a recent Antimicrobial Agents and Chemotherapy study, researchers confirmed a new drug compound kills drug-resistant C. auris, both in the laboratory and in a mouse model that mimics human infection.
APX001, the prodrug of the active moiety APX001A, is currently in clinical development by Amplyx Pharmaceuticals. It works through a novel mechanism of action. Unlike other antifungal agents that poke holes in yeast cell membranes or inhibit sterol synthesis, the new drug targets an enzyme called Gwt1, which is required for anchoring critical proteins to the fungal cell wall. This means C. auris can’t grow properly and has a harder time forming drug-resistant fungal biofilms that are a stubborn source of hospital outbreaks. Gwt1 is highly conserved across fungal species, suggesting the new drug could treat a broad range of fungal infections.
“The drug is first in a new class of antifungals, which could help stave off drug resistance. Even the most troublesome strains are unlikely to have developed workarounds for its mechanism of action,” said study lead Mahmoud A. Ghannoum, PhD, professor of dermatology at Case Western Reserve University School of Medicine and director of the Center for Medical Mycology at Case Western Reserve University and University Hospitals Cleveland Medical Center.
In the new study, Ghannoum’s team tested the drug against 16 different C. auris strains, collected from infected patients in Germany, Japan, South Korea, and India. When they exposed the isolates to the new drug, they found it more potent than nine other currently available antifungals. According to the authors, the concentration of study drug needed to kill C. auris growing in laboratory dishes was “eight-fold lower than the next most active drug, anidulafungin, and more than 30-fold lower than all other compounds tested.”
The researchers also developed a new mouse model of invasive C. auris infection for the study. Said Ghannoum, “To help the discovery of effective drugs it will be necessary to have an animal model that mimics this infection. Our work helps this process in two ways: first we developed the needed animal model that mimics the infection caused by this devastating yeast, and second, we used the developed model to show the drug is effective in treating this infection.”
Ghannoum studied immunocompromised mice infected with C. auris via their tail vein—similar to very sick humans in hospitals who experience bloodstream infections. Infected mice treated with APX001 and anidulafungin had significant reductions in kidney and lung fungal burden two days post-treatment, compared to control animals. APX001 also significantly decreased fungal burden in the brain, consistent with brain penetration, whereas reduction with anidulafungin did not reach significance. The results suggest the new drug could help treat even the most invasive infections.
According to Ghannoum, the most exciting element of the study is that it brings a promising antifungal one step closer to patients. It helps lay the foundation for phase 2 clinical trials that study that study the safety and efficacy of new drugs in patients with fungal infections. There is an urgent need for such studies, as C. auris infection has become a serious threat to healthcare facilities worldwide—and resistance to commercially available antifungal drugs is rising.
“Limited treatment options calls for the development of new drugs that are effective against this devastating infection,” Ghannoum said. “We hope that we contributed in some way towards the development of new drugs.”
The Latest on: Antifungal
via Google News
The Latest on: Antifungal
- Antifungal Drugs Market Development Strategy, Opportunity Assessment, Key Players And Trends By Forecast 2028on July 29, 2022 at 9:04 am
antifungal drugs market size was USD 11.93 Billion in 2020 and is expected to register a revenue CAGR of 1.4% during the forecast period NEW YORK CITY, NY, UNITED STATES, July 29, 2022 ...
- Mitigation of Human-Pathogenic Fungi That Exhibit Resistance to Medical Agents: Can Clinical Antifungal Stewardship Help?on July 27, 2022 at 5:00 pm
Provide cost-efficient care through optimal resource utilization and appropriate antifungal drug choice. Reduce indiscriminate use of fungicides and establish evidence-based treatment guidelines.
- Pharmacoeconomics of Empirical Antifungal Use in Febrile Neutropenic Hematological Malignancy and Hematopoietic Stem Cell Transplant Patientson July 26, 2022 at 5:00 pm
In conclusion, prescribing the most cost-effective empirical antifungal agent remains a challenge, given the limited clinical and pharmacoeconomic data available. Existing studies have ...
- Biomarker-guided therapy for fungal sepsis produces no better outcomeson July 21, 2022 at 1:24 pm
The biomarker led to earlier and more frequent antifungal therapy but could not reduce mortality. Because modern medicine enables the treatment of seriously ill and severely immunocompromised ...
- Antifungal Drugs Market Growth Opportunity, Trend, Size, Major Companies, Forecast 2030 | Revenue $25.0 Billionon July 21, 2022 at 10:04 am
Global Antifungal Drugs Market generated $16.6 billion in 2020, and is projected to reach $25.0 billion by 2030, witnessing a CAGR of 3.9% from 2021 to 2030. Rise in prevalence of chronic diseases ...
- Zydus gets USFDA nod to market generic antifungal medicationon July 18, 2022 at 3:54 am
Efinaconazole is an antifungal used for the topical treatment of Onychomycosis of the toenails due to Trichophyton rubrum and Trichophyton mentagrophytes. The drug will be manufactured at the group's ...
- Antifungal Drugs Market: Valuable Growth Prospects, Market Size, Share, Demand and Current Trends Analysis and Forecast: 2022-2031on July 13, 2022 at 8:05 am
Japan, Japan, Wed, 13 Jul 2022 02:38:44 / Comserve Inc. / -- The antifungal drugs market is estimated to represent a global market of USD 13.8 billion by 2025 with growth rate of 1.9%. The ...
- Antifungal Drugs Market Import-Export Details, Production Information 2022-2029 : Sanofi-Aventis, Novartis, Pfizer Inc, Abbott Laboratorieson July 6, 2022 at 7:47 am
Global Antifungal Drugs Market Research 2022-2031 published by Calibre Research studies the current situation, Antifungal Drugs market size, share, trends, regional growth and the latest ...
- Global Antifungal Agents Market Is Projected To Grow At An Exemplary Growth Rate of Around 2.63% By 2028 | 110 Report Pageson July 4, 2022 at 2:16 am
The Global Antifungal Agents Market Size was estimated at USD 11092.19 million in 2021 and is projected to reach USD 13299.00 million by 2028, exhibiting a CAGR of 2.63% during the forecast period.
via Bing News